FRC
FRC Logo
Sign InGet Access

Connect With Us

Stay updated with our latest research and insights

Fundamental Research Corp Logo

Highly ranked equity research firm providing institutional grade tools and analysis to all investors worldwide. Trusted by global investors for over 20+ years.

20+ Years
Rate us on TrustpilotLeave a review

Policies

  • Privacy Policy
  • Terms of Service
  • Disclaimer

Company

  • About Us
  • Our Team
  • Contact Us
  • Leave a Review

Resources

  • Videos
  • Research Reports
  • FAQ
  • How to use FRC

Browse

  • Stock Directory
  • Stock Screener
  • Market Intel Weekly
  • Report Archive

Trackers

  • Congress Trading
  • Senate Trading
  • Congress Net Worth
  • Commodities

© 2026 Fundamental Research Corp. All Rights Reserved.

Professional investment research since 2003

Home
Research
Get Access
Sign In
electroCore, Inc. Stock AnalysisComprehensive stock analysis for electroCore, Inc. (ECOR) including live price, Snowflake performance metrics, financial statements, and investment research.Stock AnalysisECOR
ECOR
electroCore, Inc.
  • Company Overview
  • FRC Research
  • Financial Data
  • Peer Comparison
  • Ownership & News
ECOR
Home🔹Stocks🔹electroCore, Inc.

electroCore, Inc.

🇺🇸ECOR•NASDAQ

electroCore, Inc.

🇺🇸ECOR•NASDAQ
Market cap
$86.73M
Sentiment

Your view on ECOR

Mkt Cap
$86.73M
Sentiment
Your view
ECOR
electroCore, Inc.
  • Company Overview
  • FRC Research
  • Financial Data
  • Peer Comparison
  • Ownership & News
ECOR
Company Overview

Overview

What the company does, where it operates, and who runs it.

About electroCore, Inc.

Industry
Medical - Devices
Sector
Healthcare
CEO
Daniel S. Goldberger
Headquarters
200 Forge Way, Rockaway, NJ, US
Industry
Medical - Devices
Sector
Healthcare
CEO
Daniel S. Goldberger
Headquarters
200 Forge Way, Rockaway, NJ, US
Description

electroCore, Inc., a commercial stage medical device company, engages in the development and commercialization of a range of non-invasive vagus nerve stimulation (nVNS) therapies. The company is developing gammaCore, a prescription-only nVNS therapy for the acute treatment of pain associated with migraine and episodic cluster headache in adults.

Its lead product is gammaCore Sapphire, a rechargeable and reloadable handheld device for regular or intermittent use over many years. The company was incorporated in 2005 and is headquartered in Rockaway, New Jersey.

FRC Research

Media

Infographics, videos, and posts covering the company.

Financial Data

Stock Data

Price chart, volume, and trading data.

Fair Value

What FRC thinks it is worth vs. the current price.

FRC's fair value estimate for electroCore, Inc., and the rating behind it. ECOR last traded at $9.62; the estimate is read against that market price. FRC analysts run the firm's valuation model across the companies on this platform to estimate what each one is worth, rather than republishing a consensus average. Shows the current estimate, our rating, and when it was last revised. A free account covers 7 company valuations a month; a paid subscription is unlimited.

Financial Ratios

Profitability, returns, valuation, and leverage ratios.

Valuation, profitability, liquidity and leverage ratios for electroCore, Inc.. Starting points for electroCore, Inc.: EPS -$1.57, beta 1.01 — an Medical - Devices name. P/E, P/B, EV/EBITDA, margins, return on equity, current ratio and debt coverage, each shown against the company's own history.

Dividend Analysis

Yield, payout ratio, and dividend coverage metrics.

Dividend history, yield and payout sustainability for electroCore, Inc.. electroCore, Inc. does not currently pay a regular dividend, so this section tracks capacity rather than history. Per-share payments, yield over time, payout ratio and growth streak, with coverage measured against free cash flow.

Earnings Analysis

EPS history, beat rate, and upcoming earnings reports.

Reported vs. expected earnings history for electroCore, Inc.. Trailing twelve-month EPS for electroCore, Inc. stands at -$1.57. EPS surprises by quarter, revenue against estimates, and the upcoming reporting date.

Financial Statements

Income statement, balance sheet, and cash flow statements.

Income statement, balance sheet and cash flow history for electroCore, Inc.. electroCore, Inc. has reported as a listed company since 2018. Annual and quarterly filings with period-over-period comparison, so you can trace how revenue, margins and cash generation have moved.

Peer Comparison

Comparables

List of peer companies in the same industry.

electroCore, Inc. valued side by side against its closest peers. electroCore, Inc. is measured against Medical - Devices peers within the Healthcare sector. Peer-relative multiples and operating metrics, so the valuation is read in the context of its own sector rather than in isolation.

Ownership & News

Institutional Ownership

Premium

Which funds and firms own the stock.

Which institutions hold electroCore, Inc., and how their positions are changing. At a $86.7M market value, institutional positions materially move electroCore, Inc.'s register. Top holders, position sizes, and quarter-over-quarter accumulation or distribution from regulatory filings. Included with FRC Premium.

Insider Trading

Premium

Recent buying and selling by company executives.

Buying and selling by electroCore, Inc. executives and directors. Shares of electroCore, Inc. have traded between $4.16 and $19.49 over the past 52 weeks — context for the timing of the transactions below. Insider transactions as disclosed to regulators, with role, size and date — the clearest read on how the people running the company are positioned. Included with FRC Premium.

Senate Trading

Premium

U.S. Senator disclosures filed under the STOCK Act.

U.S. Senate disclosures naming electroCore, Inc.. electroCore, Inc. is a $86.7M Healthcare company. Senators' reported transactions in this security, alongside the fundamentals — a signal most research platforms leave out entirely. Included with FRC Premium.

House Trading

Premium

U.S. Representative disclosures filed under the STOCK Act.

U.S. House of Representatives disclosures naming electroCore, Inc.. Representatives' reported transactions in this security, shown next to the company's fundamentals. Included with FRC Premium.

News

Latest headlines and market coverage.

Latest headlines and company announcements for electroCore, Inc.. Coverage tracks electroCore, Inc. within Medical - Devices (Healthcare). Press releases and market coverage, newest first.

Peer companies

  • BTAI — BioXcel Therapeutics, Inc.
  • HYPD — Hyperion DeFi, Inc.
  • MAIA — MAIA Biotechnology, Inc.
  • MYO — Myomo, Inc.
  • NMTC — NeuroOne Medical Technologies Corporation
  • PYPD — PolyPid Ltd.
  • RBOT — Vicarious Surgical Inc.
  • RNXT — RenovoRx, Inc.

More Medical - Devices companies

  • CTKB — Cytek Biosciences, Inc.
  • CTSO — Cytosorbents Corporation
  • CV — CapsoVision, Inc.
  • CVRX — CVRx, Inc.
  • CYBQF — CYBERDYNE Inc.
  • CYBQY — CYBERDYNE Inc.
  • CYC.AX — Cyclopharm Limited
  • CYDX — CYduct Diagnostics, Inc.
  • DCTH — Delcath Systems, Inc.
  • DGWPF — Drägerwerk AG & Co. KGaA
  • DHAI — DIH Holding US, Inc.
  • DROR — Dror Ortho-Design, Inc.

ETFs holding electroCore, Inc.

  • GWX — State Street SPDR S&P International Small Cap ETF (0.05%)
  • IWC — iShares Micro-Cap ETF (0.01%)
  • VXF — Vanguard Extended Market ETF (0.00%)
  • VUS.TO — Vanguard U.S. Total Market Index ETF (CAD-hedged) (0.00%)
  • VUN.TO — Vanguard U.S. Total Market Index ETF (0.00%)
  • VTS.AX — Vanguard U.S. Total Market Shares Index ETF (0.00%)
  • VTI — Vanguard Total Stock Market ETF (0.00%)
  • VEQT.TO — Vanguard All-Equity ETF Portfolio (0.00%)

News

Latest Market News